Tokyo Tape
Sign in
← PeptiDream

Half-year report · HY

4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥9.2bn2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥18.5bn2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income−¥2.5bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.7bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥5.3bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥72.2bnat 2026-06-30Cons.Assets IFRS
Total assets¥77.0bnat 2025-12-31Cons.Assets IFRS
Total assets¥78.5bnat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥23.7bnat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥25.5bnat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥48.6bnat 2026-06-30Cons.Equity IFRS
Net assets / equity¥51.5bnat 2025-12-31Cons.Equity IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31vCons.Equity IFRS
Equity (owners)¥48.6bnat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥51.5bnat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥23.6bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥28.7bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.8bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥13.3bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥614m2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥4.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-15.512026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-28.992025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-15.512026-01-01 → 2026-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-28.992025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio67.2%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.9%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥512m
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥512m
Drug Discovery And Development Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentsegment profit2026-01-01 → 2026-06-30−¥2.7bn
Radiopharmaceuticals Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥8.5bn
Radiopharmaceuticals Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥8.0bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥512m
Radiopharmaceuticals Businessreportable segmentsegment profit2026-01-01 → 2026-06-30¥242m
—segment totalrevenue2026-01-01 → 2026-06-30¥9.7bn
—segment totalrevenue external2026-01-01 → 2026-06-30¥9.2bn
—segment totalrevenue intersegment2026-01-01 → 2026-06-30¥512m
—segment totalsegment profit2026-01-01 → 2026-06-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 571
ItemContextValueUnit
Net cash provided by used in financing activities IFRSPrior1InterimDuration-2479216000JPY
Net cash provided by used in financing activities IFRSInterimDuration-2709586000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1InterimDuration-70404000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSInterimDuration63810000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1InterimDuration-14789711000JPY
Net increase decrease in cash and cash equivalents IFRSInterimDuration-5080112000JPY
Cash and cash equivalents IFRSPrior2YearInstant48117933000JPY
Cash and cash equivalents IFRSPrior1YearInstant28682933000JPY
Cash and cash equivalents IFRSPrior1InterimInstant33328222000JPY
Cash and cash equivalents IFRSInterimInstant23602821000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember760735000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7783052000JPY
Revenue from external customers IFRSPrior1InterimDuration_ReportableSegmentsMember8543788000JPY
Revenue from external customers IFRSPrior1InterimDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1InterimDuration8543788000JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember453484000JPY
Intersegment revenue IFRSPrior1InterimDuration_ReportableSegmentsMember453484000JPY
Intersegment revenue IFRSPrior1InterimDuration_ReconcilingItemsMember-453484000JPY
Intersegment revenue IFRSPrior1InterimDuration－JPY
Revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember760735000JPY
Revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember8236536000JPY
Revenue IFRSPrior1InterimDuration_ReportableSegmentsMember8997272000JPY
Revenue IFRSPrior1InterimDuration_ReconcilingItemsMember-453484000JPY
Revenue IFRSPrior1InterimDuration8543788000JPY
Segment profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember-3016609000JPY
Segment profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember435766000JPY
Segment profit loss IFRSPrior1InterimDuration_ReportableSegmentsMember-2580842000JPY
Segment profit loss IFRSPrior1InterimDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSPrior1InterimDuration-2580842000JPY
Business combination related expenses IFRSPrior1InterimDuration45000000JPY
Operating profit loss IFRSPrior1InterimDuration-2625842000JPY
Finance income IFRSPrior1InterimDuration162294000JPY
Finance costs IFRSPrior1InterimDuration367059000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1InterimDuration-31905000JPY
Profit loss before tax IFRSPrior1InterimDuration-2862513000JPY
Revenue from external customers IFRSInterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember1201136000JPY
Revenue from external customers IFRSInterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember8025834000JPY
Revenue from external customers IFRSInterimDuration_ReportableSegmentsMember9226971000JPY
Revenue from external customers IFRSInterimDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSInterimDuration9226971000JPY
Intersegment revenue IFRSInterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSInterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember511788000JPY
Intersegment revenue IFRSInterimDuration_ReportableSegmentsMember511788000JPY
Intersegment revenue IFRSInterimDuration_ReconcilingItemsMember-511788000JPY
Intersegment revenue IFRSInterimDuration－JPY
Revenue IFRSInterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember1201136000JPY
Revenue IFRSInterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember8537622000JPY
Revenue IFRSInterimDuration_ReportableSegmentsMember9738759000JPY
Revenue IFRSInterimDuration_ReconcilingItemsMember-511788000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass